Impact of empagliflozin on first and recurrent events leading to or prolonging hospitalisation in the EMPA-REG OUTCOME trial
Authors' conclusion
Effects were sustained and were consistent regardless of the reason for hospitalisation.
Study context
- Population
- Patients with T2D and ASCVD
- Comparison
- Empagliflozin vs placebo
- Primary endpoint
- Composite of:
- Total events leading to/prolonging hospitalisation for any cause
- All-cause mortality
Methodological detailsplacebo-controlled
- Placebo-controlled
Primary result
As reported in the abstract
Total events leading to/prolonging hospitalisation for any cause and all-cause mortality
Events prevented/1000 patient-years
67.7
Further findings
Consistency by reason for hospitalisation
- Effects were sustained and were consistent regardless of the reason for hospitalisation
Original publication
Impact of empagliflozin on first and recurrent events leading to or prolonging hospitalisation in the EMPA-REG OUTCOME trial. Diabetes Res Clin Pract. Published 21 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →